Clinical Trials Browser

Phase 2/3 × Terminated × Paclitaxel × Clear all

NCT05870748 2025-09-23

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Phase 2/3 Terminated

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06321068 2025-08-14

BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

Phase 2/3 Terminated

Endometrial Neoplasms

NCT01704690 2017-04-07

Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer

Phase 2/3 Terminated

Gastrointestinal

Esophageal Neoplasms

NCT01383148 2017-01-05

TIME

Phase 2/3 Terminated

Carcinoma, Non-Small-Cell Lung

NCT00003880 2015-04-16

Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer

Phase 2/3 Terminated

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00507429 2014-06-09

FACT

Phase 2/3 Terminated

80 enrolled 10 charts

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic